文献速递银屑病与炎症性皮肤病

免疫介导炎症性疾病患者中肿瘤坏死因子-α抑制剂治疗与新发银屑病的绝对和相对风险:一项丹麦全国性队列研究

Absolute and Relative Risk of New-Onset Psoriasis Associated With Tumor Necrosis Factor-α Inhibitor Treatment in Patients With Immune-Mediated Inflammatory Diseases: A Danish Nationwide Cohort Study.
PubMed 文献 · JAMA Dermatol · 2022-01-01

该丹麦全国性队列研究(1995-2018)纳入109 085例免疫介导炎症性疾病患者,比较肿瘤坏死因子-α抑制剂(TNFi)与常规治疗的新发银屑病风险。TNFi治疗者非脓疱型银屑病风险比为2.12(95%CI 1.87-2.40),脓疱型银屑病风险比为6.50(95%CI 4.60-9.23),但绝对风险差异约为每1000患者年5例,作者认为不应改变需要TNFi治疗患者的治疗策略。

要点

  • TNFi治疗者新发非脓疱型银屑病风险比为2.12(95%CI 1.87-2.40;P < .001)。
  • TNFi治疗者新发脓疱型银屑病风险比为6.50(95%CI 4.60-9.23;P < .001)。
  • 每增加1例任何类型TNFi相关银屑病需暴露241患者年,绝对风险差异约每1000患者年5例。

核心结论

  • 在无银屑病史的免疫介导炎症性疾病患者中,TNFi治疗者非脓疱型银屑病事件数最多,而脓疱型银屑病的相对风险最高。
  • 尽管TNFi治疗者新发非脓疱型和脓疱型银屑病风险均增加,但绝对风险仍较有限,每增加1例事件需241患者年暴露,估计绝对风险差异约为每1000患者年5例,表明需要TNFi治疗患者的治疗策略不应改变。

研究设计与样本

  • 研究使用丹麦全国登记数据(1995-2018),为队列研究,纳入接受常规治疗或TNFi治疗的炎症性肠病和/或类风湿关节炎患者。
  • 纳入患者总计109 085例,其中62%为女性,中位年龄(IQR)为50(34-64)岁。
  • 108 024例接受常规治疗,20 910例接受TNFi治疗;患者随访至多5年,数据分析时间为1995年1月至2018年12月。
  • 采用具有稳健方差的Cox回归模型比较任何类型银屑病、非脓疱型银屑病和脓疱型银屑病的发生风险,以接受常规治疗的患者为参照。

主要发现

  • 随访期间,1471例(1.4%)患者发生任何类型银屑病,其中1332例发生非脓疱型银屑病,127例发生掌跖脓疱病,12例发生泛发性脓疱病。
  • 任何类型银屑病的发病率(每1000患者年)在常规治疗组为3.0(95%CI 2.9-3.2),在TNFi组为7.8(95%CI 7.5-8.9)。
  • 与常规治疗相比,TNFi治疗期间发生非脓疱型银屑病的风险比为2.12(95%CI 1.87-2.40;P < .001),发生脓疱型银屑病的风险比为6.50(95%CI 4.60-9.23;P < .001)。
  • 每增加1例任何类型TNFi相关银屑病需暴露241患者年,非脓疱型银屑病为342患者年,脓疱型银屑病为909患者年。

关键数值与推荐

  • 任何类型银屑病的结局定义为登记有国际疾病统计分类第十版银屑病编码和/或连续2次外用维生素D类似物处方。
  • 常规治疗指非生物制剂治疗;生物制剂治疗区分为TNFi治疗和非TNFi生物制剂治疗。

临床怎么用

  • 作者认为,需要TNFi治疗患者的治疗策略不应改变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Tumor necrosis factor-α inhibitor (TNFi)-associated psoriasis is a rare adverse event following TNFi treatment. Data on the risk of developing TNFi-associated psoriasis when treated with TNFi are sparse. OBJECTIVE: To investigate the associated risk between new-onset psoriasis and TNFi treatment compared with nonbiologic conventional treatment. DESIGN, SETTING, AND PARTICIPANTS: Using Danish national registries (1995-2018), this cohort study included patients with inflammatory bowel disease (IBD) and/or rheumatoid arthritis (RA) who received either conventional therapy or TNFi treatment. Patients may not have been diagnosed with psoriasis prior to initiation of treatment. Patients were followed up for up to 5 years. Cox regression models with robust variance were used to compare the risk of developing any type of psoriasis, nonpustular psoriasis, and pustular psoriasis. Patients receiving conventional therapy were used as reference. Data analysis was performed from January 1995 to December 2018. EXPOSURES: For the present study, the term conventional therapy was used for the nonbiological therapy. For biological therapy, a distinction was made between TNFi treatment and non-TNFi biological therapy. MAIN OUTCOMES AND MEASURES: The outcome of psoriasis was defined as a registered International Statistical Classification of Diseases and Related Health Problems, Tenth Revision code of psoriasis and/or having 2 consecutive prescriptions of topical vitamin D analogues. RESULTS: The study included 109 085 patients, of which 62% were female. Median (IQR) age was 50 (34-64) years. Of the included patients, 108 024 received conventional therapy and 20 910 received TNFi treatment. During follow-up, 1471 (1.4%) patients developed any type of psoriasis, of which 1332 developed nonpustular psoriasis, 127 patients developed palmoplantar pustulosis, and 12 patients developed generalized pustulosis. The incidence rates for developing any type of psoriasis per 1000 patient-years were 3.0 (95% CI, 2.9-3.2) for conventional therapy and 7.8 (95% CI, 7.5-8.9) for TNFi. During treatment with TNFi, the hazard ratio was 2.12 (95% CI, 1.87-2.40; P < .001) for developing nonpustular psoriasis and 6.50 (95% CI, 4.60-9.23; P < .001) for pustular psoriasis compared with conventional treatment. Exposure needed for 1 additional patient to be harmed was 241 patient-years for any type of TNFi-associated psoriasis, 342 patient-years for nonpustular psoriasis, and 909 patient-years for pustular psoriasis. CONCLUSIONS AND RELEVANCE: In a Danish nationwide cohort of patients with immune-mediated inflammatory diseases treated with TFNi or conventional treatment and no history of psoriasis, in TFNi-treated patients, nonpustular types of psoriasis constituted the most events, whereas pustular types of psoriasis had the highest relative risk. Although the risk of new-onset psoriasis increased for both nonpustular and pustular types of psoriasis in TFNi-treated patients, the absolute risk remained modest at 241 patient-years of exposure need for 1 additional event and an estimated absolute risk difference around 5 per 1000 patient-years, indicating that the approach to treatment of patients in need of TNFi treatment should not change.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Thein D, Egeberg A, Skov L, et al. Absolute and Relative Risk of New-Onset Psoriasis Associated With Tumor Necrosis Factor-α Inhibitor Treatment in Patients With Immune-Mediated Inflammatory Diseases: A Danish Nationwide Cohort Study. JAMA Dermatol. 2022. PMID: 35767240. doi:10.1001/jamadermatol.2022.2360

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。